1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Granulocytic Leukemia in 9 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The dose-response and the time-course of the inhibitor, however, indicated that the site of action of TPCK for NF-kappa B activation and for DNA fragmentation are quite distinct." | 1.29 | Protease inhibitors differentially regulate tumor necrosis factor-induced apoptosis, nuclear factor-kappa B activation, cytotoxicity, and differentiation. ( Aggarwal, BB; Chan, H; Higuchi, M; Singh, S, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Higuchi, M | 1 |
| Singh, S | 1 |
| Chan, H | 1 |
| Aggarwal, BB | 1 |
| Laredo, J | 1 |
| Demur, C | 1 |
| Muller, C | 1 |
| Saivin, S | 1 |
| Cassar, G | 1 |
| Bousquet, C | 1 |
| Dastugue, N | 1 |
| Jaffrézou, JP | 1 |
| Colombies, P | 1 |
| Laurent, G | 1 |
| Yamamoto-Yamaguchi, Y | 1 |
| Okabe-Kado, J | 1 |
| Kasukabe, T | 1 |
| Honma, Y | 1 |
| Matikainen, S | 1 |
| Serkkola, E | 2 |
| Hurme, M | 2 |
| Bernstein, SH | 1 |
| Kharbanda, SM | 1 |
| Sherman, ML | 1 |
| Stone, RM | 1 |
| Kufe, DW | 1 |
| Cost, H | 1 |
| Barreau, P | 1 |
| Basset, M | 1 |
| Le Peuch, C | 1 |
| Geny, B | 1 |
| Ronni, T | 1 |
| Silvennoinen, O | 1 |
| Shibanuma, M | 1 |
| Kuroki, T | 1 |
| Nose, K | 1 |
| Osada, H | 1 |
| Magae, J | 1 |
| Watanabe, C | 1 |
| Isono, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
| A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy[NCT01869114] | Phase 2 | 57 participants (Actual) | Interventional | 2013-07-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Granulocytic Leukemia
| Article | Year |
|---|---|
Protease inhibitors differentially regulate tumor necrosis factor-induced apoptosis, nuclear factor-kappa B activation, cytotoxicity, and differentiation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Apoptosis; Base Sequence; Cell Differentiation; Cyclo | 1995 |
Effects of H-7 and staurosporine on proliferation and self-renewal of acute myeloid leukemia progenitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Alkaloids; Antineoplastic Agents; Cell C | 1993 |
Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Benzylamines; Calcium-Calmodulin-Dependent Protein Ki | 2001 |
Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Benzylamines; Calcium-Calmodulin-Dependent Protein Ki | 2001 |
Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Benzylamines; Calcium-Calmodulin-Dependent Protein Ki | 2001 |
Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Benzylamines; Calcium-Calmodulin-Dependent Protein Ki | 2001 |
Retinoic acid enhances IL-1 beta expression in myeloid leukemia cells and in human monocytes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Blotting, Northern; Bucladesine; Gene Expression; Hum | 1991 |
Inhibition of protein kinase C is associated with a decrease in c-myc expression in human myeloid leukemia cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkaloids; Blotting, Northern; Cell Line; Enzyme Acti | 1991 |
Phorbol myristate acetate inhibits phosphoinositol lipid-specific phospholipase C activity via protein kinase C activation in conditions inducing differentiation in HL-60 cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkaloids; Cell Differentiation; Cell Membrane; Clone | 1991 |
Control of interleukin-1 beta expression by protein kinase C and cyclic adenosine monophosphate in myeloid leukemia cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Bucladesine; Colforsin; Cyclic AMP; Dinoprostone; Enz | 1990 |
Effects of the protein kinase C inhibitor H-7 and calmodulin antagonist W-7 on superoxide production in growing and resting human histiocytic leukemia cells (U937).
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Calmodulin; Cell Division; Cell Line; Humans; Isoquin | 1987 |
Rapid screening method for inhibitors of protein kinase C.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actinomycetales; Alkaloids; Anti-Bacterial Agents; Dr | 1988 |